- Home
- Companies
- united kingdom
- therapeutic candidate
Show results for
Refine by
Therapeutic Candidate Suppliers In United Kingdom
5 companies found
based inCambridge, UNITED KINGDOM
GW is the global leader in developing cannabinoid-based medicines. GW has been researching cannabinoids since 1998 and has established a world leading position in the development of plant-derived cannabinoid therapeutics. GW has established a world ...
based inSomerset, NEW JERSEY (USA)
As the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world, we conduct all our business responsibly and with integrity. Our ...
To date, over 600 different mAb and mAb fusions and over 160+ different recombinant proteins have been produced using the GPEx system, with 160+ clinical trials utilizing therapeutic candidates developed using GPEx ...
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and patients. Our TCR T-cell therapies have advantages over other immune ...
based inNewcastle Upon Tyne, UNITED KINGDOM
Newcells offers expert disease modelling services using best in class in vitro platforms and supports drug development by providing robust data for regulatory submissions and the critical decision-making process. Newcells mission is to de-risk the ...
In vitro assessment of Fibroblast-to-Myofibroblast transition (FMT). Newcells offers a fast and reliable FMT assay service to evaluate the efficacy of anti-fibrotic compounds using high-content imaging. This customisable, high-throughput assay is ...
based inOxford, UNITED KINGDOM
Orbit was founded By Professor Terry Rabbitts and Professor Graham Ogg in 2015 as a spin-out from the University of Oxford. The company’s focus is to identify therapeutic peptides using its unique peptide display platform. In 2021 the organisation ...
The Orbit Discovery Affinity Screening platform offers a proprietary technology enabling the construction of massive bead-based libraries with peptides displayed on their surface. Each bead carries a unique DNA sequence, which is translated into ...